Arca
Skip to content
Tools
Tools

Label Changes: Scemblix (asciminib hydrochloride)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Scemblix label DailyMed has published, from Novartis Pharmaceuticals Corporation, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 13
  • Sections changed, version 12 to 13: 4

What changed from version 12 to version 13

Dec 5, 2025 to Sep 29, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Drug interactionsChanged ยท 55 words added, 41 removed
  2. Clinical pharmacologyChanged ยท 280 words added, 124 removed
  3. Patient counseling informationChanged ยท 2 words added, 2 removed
  4. Patient informationChanged ยท punctuation or symbols only

Drug interactions

Changed55 words added, 41 removed
17 unchanged lines
Asciminib is a P-gp inhibitor. Concomitant use of SCEMBLIX increases the plasma concentrations of P-gp substrates, which may increase the risk of adverse reactions of these substrates [see Clinical Pharmacology (12.3)].
Closely monitor for adverse reactions in patients treated with SCEMBLIX at all recommended doses with concomitant use of P-gp substrates, where minimal concentration changes may lead to serious toxicities.
Closely monitor for adverse reactions in patients treated with SCEMBLIX at all recommended doses with concomitant use of P-gp substrates, where minimal concentration changes may lead to serious toxicities. Adjust the dosage of these P-gp substrates, as recommended in their Prescribing Information, when used concomitantly with SCEMBLIX at all recommended doses.
Substrates of BCRP
Asciminib is a BCRP inhibitor. Concomitant use of SCEMBLIX may increase the plasma concentration of BCRP substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions associated with these substrates.
Avoid coadministration of SCEMBLIX at all recommended doses with rosuvastatin. Closely monitor for adverse reactions in patients treated with SCEMBLIX at all recommended doses with concomitant use of rosuvastatin or other BCRP substrates. Reduce the dosage of the other BCRP substrates as recommended in their Prescribing Information when used concomitantly with SCEMBLIX at all recommended doses.

Clinical pharmacology

Changed280 words added, 124 removed
40 unchanged lines
Drugs That Affect Asciminib Plasma Concentration
Strong CYP3A Inhibitors: The asciminib AUCinf and Cmax increased by 1.36%-fold and 1.19%-fold, respectively, following coadministration of a single SCEMBLIX dose of 40 mg with a strong CYP3A4 inhibitor (clarithromycin). No clinically significant differences in the pharmacokinetics of asciminib were observed when coadministered with itraconazole, which is also a strong CYP3A4 inhibitor.
Strong CYP3A Inducers: The asciminib AUCinf decreased byto 3466% and Cmax decreased byto 2278% following coadministration of a single SCEMBLIX dose of 200 mg with a strong CYP3A4 inducer (phenytoin) 100 mg three times daily. The asciminib AUCinf decreased byto 1585% while Cmax increased by 9%, 1.09-fold following coadministration of a single SCEMBLIX dose of 40 mg with a strong CYP3A4 inducer (rifampicin).
Itraconazole Oral Solution: Coadministration of multiple doses of itraconazole oral solution containing hydroxypropyl-ฮฒ-cyclodextrin with a single SCEMBLIX dose of 40 mg decreased asciminib AUCinf and Cmax by 40% and 50%, respectively. Concomitant use of oral products containing hydroxypropyl-ฮฒ-cyclodextrin with SCEMBLIX other than itraconazole oral solution has not been fully characterized.
Itraconazole Oral Solution: The asciminib AUCinf and Cmax decreased to 60% and 50%, respectively, following coadministration of a single SCEMBLIX dose of 40 mg with multiple doses of itraconazole oral solution containing hydroxypropyl-ฮฒ-cyclodextrin. Concomitant use of oral products containing hydroxypropyl-ฮฒ-cyclodextrin with SCEMBLIX other than itraconazole oral solution has not been fully characterized.
Imatinib: The asciminib AUCinf and Cmax increase byincreased 108%2.08-fold and 1.59%-fold, respectively following coadministration of a single SCEMBLIX dose of 40 mg with imatinib (an inhibitor of BCRP, CYP3A4, UGT2B17, and UGT1A3/4). The exposure changes are not considered clinically meaningful. Concomitant use of imatinib with SCEMBLIX at 200 mg twice daily has not been fully characterized.
Other Drugs: No clinically significant differences in the pharmacokinetics of asciminib were observed when coadministered with rabeprazole (acid-reducing agent) and quinidine (P-gp inhibitor).
Drugs That are Affected by Asciminib
CYP3A4 Substrates: The midazolam AUCinf and Cmax increased by 1.28%-fold and 1.11%-fold, respectively, following coadministration of a CYP3A4 substrate (midazolam) with SCEMBLIX 40 mg twice daily. The midazolam AUCinf and Cmax increased by 1.24%-fold and 1.17%-fold, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 1.88%-fold and 1.58%-fold, respectively, at 200 mg twice daily.
CYP2C9 Substrates: The S-warfarin AUCinf and Cmax increased by 1.41%-fold and 8%1.08-fold, respectively, following coadministration of CYP2C9 substrate (warfarin) with SCEMBLIX at 40 mg twice daily. The S-warfarin AUCinf and Cmax increased by 1.52%-fold and 4%1.04-fold, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 314%4.14-fold and 7%1.07-fold, respectively, at 200 mg twice daily.
CYP2C8 Substrates: The repaglinide (substrate of CYP2C8, CYP3A4, and OATP1B) AUCinf and Cmax increased by 8%1.08-fold and 1.14%-fold, respectively, following coadministration of repaglinide with SCEMBLIX 40 mg twice daily. The repaglinide AUCinf and Cmax increased by 1.12%-fold and 8%1.08-fold, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 1.42%-fold and 1.25%-fold, respectively, at 200 mg twice daily. The rosiglitazone (substrate of CYP2C8 and CYP2C9) AUCinf and Cmax increased by 1.20%-fold and 3%1.03-fold, respectively, following coadministration of rosiglitazone with SCEMBLIX 40 mg twice daily. The rosiglitazone AUCinf and Cmax increased by 1.24%-fold and 2%1.02-fold, respectively, following coadministration with SCEMBLIX at 80 mg once daily and 1.66%-fold and 8%1.08-fold, respectively, at 200 mg twice daily.
P-gp Substrates: Coadministration of SCEMBLIX with a drug that is a substrate of P-gp may result in a clinically relevant increase in the plasma concentrations of P-gp substrates, where minimal concentration changes may lead to serious toxicities.
P-gp Substrates: The digoxin (substrate of P-gp) AUCinf and Cmax increased 1.18-fold and 1.30-fold, respectively, following coadministration of digoxin with SCEMBLIX 80 mg once daily. Coadministration of SCEMBLIX 200 mg twice daily with a drug that is a substrate of P-gp may result in a more pronounced increase in the plasma concentrations of P-gp substrates, such that minimal concentration changes may lead to serious toxicities.
OATP1B Substrates: The atorvastatin (substrate of OATP1B, CYP3A4, and P-gp) AUCinf and Cmax increased by 1.14%-fold and 1.24%-fold, respectively, following coadministration of atorvastatin with SCEMBLIX 80 mg once daily.
BCRP Substrates: The rosuvastatin (substrate of BCRP and OATP1B) AUCinf and Cmax increased 2.18-fold and 2.82-fold, respectively, following coadministration of rosuvastatin with SCEMBLIX 80 mg once daily. Coadministration of SCEMBLIX 200 mg twice daily with a drug that is a substrate of BCRP may result in a more pronounced increase in the plasma concentrations of BCRP substrates, such that minimal concentration changes may lead to serious toxicities.
In Vitro Studies
4 unchanged lines

Patient counseling information

Changed2 words added, 2 removed
26 unchanged lines
ยฉ Novartis
T2025-68
T2026-38

Patient information

Changedpunctuation or symbols only
9 unchanged lines
The most common side effects of SCEMBLIX include:
โ€ข muscle, bone, or joint pain โ€ข rash โ€ข tiredness โ€ข nose, throat, or sinus (upper respiratory tract) infections โ€ข headache โ€ข stomach-area (abdominal) pain โ€ข diarrhea | โ€ข decreased white blood cell counts, platelet counts, and red blood cell counts โ€ข decreased blood calcium corrected levels โ€ข increased blood pancreas enzyme (lipase and amylase) levels โ€ข increased blood fat (cholesterol and triglycerides) levels โ€ข increased blood uric acid levels โ€ข increased blood liver enzyme levels โ€ข increased blood alkaline phosphatase levels โ€ข increased blood creatine kinase levels
Your healthcare provider may change your dose or temporarily or permanently stop treatment with SCEMBLIX if you have certain side effects. SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of SCEMBLIX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
5 unchanged lines

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Adverse reactions, Use in specific populations, Description, Nonclinical toxicology, Clinical studies, How supplied, Principal display panel.

Every version

13 versions of set e33001e7-3650-42b1-ae56-cddb5c43aa2b, newest first.
VersionPublished on DailyMedCompareSPL file
13Sep 29, 2026Shown belowDownload .zip
12Dec 5, 2025With version 11Download .zip
11Nov 17, 2025With version 10Download .zip
10Jun 20, 2025With version 9Download .zip
9Nov 1, 2024With version 8Download .zip
8Aug 15, 2024With version 7Download .zip
7Jul 24, 2024With version 6Download .zip
6May 1, 2024With version 5Download .zip
5Nov 13, 2023With version 4Download .zip
4Jul 3, 2023With version 3Download .zip
3Oct 20, 2022With version 2Download .zip
2Oct 10, 2022With version 1Download .zip
1Nov 2, 2021First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.